

Joanna Moes-Sosnowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997982/publications.pdf>

Version: 2024-02-01

19
papers

1,021
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

3285
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems. <i>Advances in Medical Sciences</i> , 2021, 66, 336-342.	2.1	4
2	FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC)., 2021, , .		0
3	1409P Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SqCLC) targeted therapy. <i>Annals of Oncology</i> , 2020, 31, S891.	1.2	1
4	Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression “ NGS pilot study. , 2020, , .		0
5	Clinical importance of <i>FANCD2</i> , <i>BRIP1</i> , <i>BRCA1</i> , <i>BRCA2</i> and <i>FANCF</i> expression in ovarian carcinomas. <i>Cancer Biology and Therapy</i> , 2019, 20, 843-854.	3.4	20
6	The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros. , 2019, , .		1
7	FGFR1-4 and MET expression analysis and evaluation of reliable reference genes in Sq-NSCLC. , 2019, , .		1
8	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
9	Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17735-17755.	1.8	4
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
11	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
12	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
13	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
14	Genome-wide significant risk associations for mucinous ovarian carcinoma. <i>Nature Genetics</i> , 2015, 47, 888-897.	21.4	78
15	Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 32.	2.7	31
16	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24
17	Analiza mutacji i polimorfizmów w genie <i>FANCD2</i> u pacjentek chorych na raka jajnika z populacji polskiej. <i>Nowotwory</i> , 2015, 65, 7-13.	0.3	1
18	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144

#	ARTICLE	IF	CITATIONS
19	Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4 gene inactivation. a pilot study. Polish Journal of Pathology, 2013, 4, 238-246.	0.3	85